Korean Circ J.  1997 Apr;27(4):417-425. 10.4070/kcj.1997.27.4.417.

Clinical Effects of Simvastatin in Patients with Hypercholesterolemia

• Jeong MH
• Cha KS
• Park JC
• Seo JP
• Park JH
• Cho JG
• Park JG
• Suh SP
• Park JC
• Kang JC

• KMID: 2229056
• DOI: http://doi.org/10.4070/kcj.1997.27.4.417

Abstract

BACKGROUND
To evaluate the clinical efficacy of Simvastatin, a HMG-CoA reductase inhibitor, We ibsweved the changes of clinical characteristics and lipid profiles after Simvastatin administration in patients with hypercholesterolemia.
METHODS AND RESULTS
Simvastatin 10mg was given once daily for 12 weeks in 35 patients (60+/-6.0 years : 14 male, 21 female) with hypercholesterolemia. High density lipoprotein-cholesterol (HDL-C) was increased from 38+-10 to 45+-9mg/dl(p<0.05). Simvastatin significantly decreased total cholesterol(TC) from 235+-15 to 181+-21mg/dl(23.0%), low-density lipoprotein cholesterol (LDL-C) from 164+-19 to 104+-18mg/dl(36.5%), TC/HDL-C from 7.0+-2.0 to 4.4+-1.1, LDL-C/HDL-C from 4.9+-1.7 to 2.5+-0.8(p<0.01 respectively). Apo B was decreased by 31%(119+-19 to 87+-15mg/dl), apo B/A1 ratio was decreased by 41%(1.2+-0.2 to 0.7+-0.2) amd lipoprotein(a) edcreased by 12%(33+-22 to 29+-17), while apo A1 was increased by 25%(104+-18 to 130+-23mg/dl, p<0.01 respectively). No patients complained of chest pain, but two had skin rashes. Creatine kinase and creatinine were not changed in all patients.
CONCLUSIONS
Somvastatin is an effective and well tolerated cholesterol lowering agent in patients with hypercholesterolemia.

Keyword

Simvastatin; Hypercholesterolemia; Apolipoprotein; Lipoprotein(a)

MeSH Terms

Apolipoprotein A-I
Apolipoproteins
Apolipoproteins B
Chest Pain
Cholesterol
Creatine Kinase
Creatinine
Exanthema
Humans
Hypercholesterolemia*
Lipoprotein(a)
Lipoproteins
Male
Oxidoreductases
Simvastatin*
Apolipoprotein A-I
Apolipoproteins
Apolipoproteins B
Cholesterol
Creatine Kinase
Creatinine
Lipoprotein(a)
Lipoproteins
Oxidoreductases
Simvastatin